ZNA Jan Palfijn
- Address
- lock Available on a paid plan
Immune System Diseases and Inflammatory Arthritis
At ZNA Jan Palfijn in Antwerp, the Rheumatology department is involved in studies focused on immune system diseases and chronic joint inflammation, with research centered on systemic lupus erythematosus and juvenile idiopathic arthritis. These trials are designed to evaluate new treatment options, measure symptom control, and better understand long-term safety in people living with active autoimmune disease.
- Testing new approaches for systemic lupus erythematosus to improve disease control
- Evaluating treatment effects in juvenile idiopathic arthritis for children and adolescents
- Assessing safety and longer-term outcomes for immune-targeted therapies
The site’s work in this area reflects a strong interest in advancing care for complex autoimmune conditions that affect both adults and younger patients.
Metabolic Disease, Diabetes, and Weight Management
Clinical research here also includes nutritional and metabolic diseases, especially type 2 diabetes and overweight or obesity. These studies aim to improve blood sugar control and support healthier body weight, while also exploring whether newer therapies may offer better results than current treatment approaches.
- Improving glucose control in type 2 diabetes
- Studying treatment strategies for overweight and obesity
- Comparing the effectiveness of different metabolic therapies
This research area shows a practical focus on conditions that are common, long-lasting, and closely linked to overall health.
Bone, Joint, and Pain-Related Conditions
Another important theme at ZNA Jan Palfijn is research into osteoarthritis, where the goal is to ease knee pain, improve function, and evaluate whether new treatments can help people manage daily symptoms more effectively. These studies connect rheumatology with broader efforts to improve quality of life in degenerative joint disease.
- Relieving pain and stiffness in osteoarthritis
- Assessing whether new therapies can improve mobility and comfort
- Measuring patient-reported outcomes such as pain and function
The focus is on practical benefits for people living with persistent joint problems and reduced physical activity.
Hematologic and Oncologic Research
The site also participates in studies within hemic and lymphatic diseases and neoplasms, including large B-cell lymphoma and metastatic hormone-sensitive prostate cancer. These trials are aimed at improving treatment effectiveness, supporting disease control, and testing whether newer combinations can strengthen outcomes for patients with advanced cancer.
- Evaluating new treatment strategies for large B-cell lymphoma
- Studying therapy combinations for metastatic hormone-sensitive prostate cancer
- Assessing whether novel cancer treatments can improve progression control
This area highlights the site’s contribution to research that seeks better options for hard-to-treat malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ZNA Jan Palfijn
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized open-label study to assess the efficacy, safety, and pharmacokinetics of upadacitinib with a tocilizumab reference arm in subjects from 1 year to less than 18 years old with active systemic juvenile idiopathic arthritis. | AbbVie Deutschland GmbH & Co. KG | Phase III | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tocilizumab | 2 | Unknown | 2023-10-17 | 2024-03-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.